How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,654 results for

Chronic Hepatitis B Carrier

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus Full Text available with Trip Pro

Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus Chronic infection with hepatitis B virus (HBV) occurs in approximately 6% of the world's population. Carriers of the virus are at risk for life-threatening complications, and developing curative treatment remains a priority. The main shortcoming of licensed therapies is that they do not affect viral covalently closed circular DNA (cccDNA), a stable intermediate of replication. Harnessing gene editing

2016 Molecular Therapy

182. Metabolic characterization of the natural progression of chronic hepatitis B Full Text available with Trip Pro

Metabolic characterization of the natural progression of chronic hepatitis B Worldwide, over 350 million people are chronically infected with the hepatitis B virus (HBV) and are at increased risk of developing progressive liver diseases. The confinement of HBV replication to the liver, which also acts as the central hub for metabolic and nutritional regulation, emphasizes the interlinked nature of host metabolism and the disease. Still, the metabolic processes operational during the distinct (...) clinical phases of a chronic HBV infection-immune tolerant, immune active, inactive carrier, and HBeAg-negative hepatitis phases-remains unexplored.To investigate this, we conducted a targeted metabolomics approach on serum to determine the metabolic progression over the clinical phases of chronic HBV infection, using patient samples grouped based on their HBV DNA, alanine aminotransferase, and HBeAg serum levels.Our data illustrate the strength of metabolomics to provide insight into the metabolic

2016 Genome medicine

183. Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection Full Text available with Trip Pro

Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection There are ~350 million chronic carriers of hepatitis B (HBV). While a prophylactic vaccine and drug regimens to suppress viremia are available, chronic HBV infection is rarely cured. HBV's limited host tropism leads to a scarcity of susceptible small animal models and is a hurdle to developing curative therapies. Mice that support engraftment with human hepatoctyes have

2016 Virology

184. Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration

Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02953600 Recruitment Status : Unknown Verified October 2016 by Taipei Medical University WanFang Hospital

2016 Clinical Trials

185. Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study

is that these can be determined by prospective follow-up of a population-based cohort. Aims, purpose, or objectives: To determine the characteristics of a population of asymptomatic Cameroonian adults who work for the Cameroon Baptist Convention Health Board (CBCHB) who have chronic hepatitis B infection. To determine the phase of infection into which these Hepatitis B carriers fall. To determine the incidence and risk factors for cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma in this cohort (...) ) related information: Groups and Cohorts Go to Group/Cohort hepatitis B cohort CBCHB employees and/or spouses found to be hepatitis B surface antigen positive on screening Outcome Measures Go to Primary Outcome Measures : Proportion of subjects in each phase of chronic hepatitis B infection at enrollment [ Time Frame: Enrollment ] distribution of subjects across the 4 phases of chronic hepatitis B at enrollment (immune tolerant, immune clearance, inactive carrier, and reactivation phases

2016 Clinical Trials

186. Factors Affecting the Natural Decay of Hepatitis B Surface Antigen in Children with Chronic Hepatitis B Virus Infection during Long-Term Follow-Up. (Abstract)

Factors Affecting the Natural Decay of Hepatitis B Surface Antigen in Children with Chronic Hepatitis B Virus Infection during Long-Term Follow-Up. To investigate the factors predicting spontaneous clearance of hepatitis B surface antigen (HBsAg) in a long-term, prospectively followed cohort from childhood into adult life.Children with chronic hepatitis B virus (HBV) infection without treatment were followed longitudinally every 6 months. At each visit, liver profiles and HBV markers were (...) assessed. Hepatitis B vaccination history and the maternal HBV markers also were studied.A total of 349 children (205 male) were followed for 20.6 ± 4.4 years with initial ages of 8.4 ± 3.9 years; 42 (12.0%) cleared HBsAg spontaneously. The HBsAg titers decayed with age, with an average annual clearance rate of 0.58%. Children had a lower annual HBsAg decay rate if their mothers are HBsAg carriers (P < .001). Hepatitis B e antigen-seroconversion is a favorable predictor for spontaneous HBsAg clearance

2014 Journal of Pediatrics

187. Liver enzyme concentrations as measure of possible infectivity in chronic asymptomatic carriers of hepatitis B. Full Text available with Trip Pro

Liver enzyme concentrations as measure of possible infectivity in chronic asymptomatic carriers of hepatitis B. Fifty-two British-born blood donors who were chronic carriers of hepatitis B surface antigen (HBsAg) were tested for the presence of hepatitis B e antigen (HBeAg) and antibody to HBeAg by an immunoradiometric assay. The presence of HBeAg was closely associated with a slight rise in serum liver enzyme concentrations, a high HBsAg titre, and male sex. We suggest that the finding (...) of persistently raised serum liver enzyme concentrations in an asymptomatic HBsAg carrier might be useful as a likely indicator of HBeAg and high infectivity.

1978 British medical journal

188. Guidance on prevention of viral hepatitis B and C among people who inject drugs

people are chronically infected with hepatitis B (HBV) and 170 million are chronically infected with hepatitis C (HCV). These numbers far exceed the number of people living with HIV, estimated at 34 million. People who inject drugs (PWID) are a key population affected by HBV and HCV. There are approximately 16 million people who inject drugs in 148 countries (1). In 201 1 it was estimated that 1.2 million people who inject drugs are infected with HBV and 10 million people who inject drugs (...) -based initiatives in programmes working with PWID.13 3. BaCKGROUNd It is estimated that 240 million people are chronically infected with HBV and 170 million are chronically infected with HCV (7-9). These numbers far exceed the number of people living with HIV, estimated at 34 million (10). Co-infection with viral hepatitis and HIV is increasingly seen as a major public health problem: Chronic hepatitis B virus (HBV) infection affects 10% of people living with HIV worldwide, with great variability

2012 World Health Organisation HIV Guidelines

189. Prevention of Early-Onset Group B Streptococcal Disease in Newborns

and Prevention [CDC]. MMWR Recomm Rep 2010;59(RR-10):1–36.) (This Committee Opinion, including Table 1, Box 2, and Figures 1–3, updates and replaces the obstetric components of the CDC 2010 guidelines, “Prevention of Perinatal Group B Streptococcal Disease: Revised Guidelines From CDC, 2010.”) e58 Committee Opinion Early-Onset Group B Streptococcal Disease OBSTETRICS & GYNECOLOGYpregnancy or chronic hypertension, among others) (76), planned prenatal GBS screening within 5 weeks before the scheduled delivery (...) Prevention of Early-Onset Group B Streptococcal Disease in Newborns INTERIM UPDATE ACOGCOMMITTEEOPINION Number 797 (Replaces Committee Opinion No. 782, June 2019) Committee on Obstetric Practice The American Academy of Pediatrics, the American College of Nurse-Midwives, the Association of Women’s Health, Obstetric and Neonatal Nurses, and the Society for Maternal-Fetal Medicine endorse this document. Although the American Society for Microbiology cannot endorse this document because the content

2020 American College of Obstetricians and Gynecologists

190. Prevention of Group B Streptococcal Early-Onset Disease in Newborns

Prevention of Group B Streptococcal Early-Onset Disease in Newborns Prevention of Group B Streptococcal Early-Onset Disease in Newborns | ACOG Clinical Guidance Journals & Publications Patient Education Topics Featured Clinical Topics Hi, Featured Clinical Topics Clinical Guidance Prevention of Group B Streptococcal Early-Onset Disease in Newborns Committee Opinion Number 797 February 2020 Jump to Resources Share By reading this page you agree to ACOG's Terms and Conditions. A correction (...) and Gynecologists’ (ACOG) Committee on Obstetric Practice in collaboration with the American College of Nurse-Midwives liaison member Tekoa L. King, CNM, MPH; ACOG Committee on Obstetric Practice committee member Neil S. Silverman, MD; and ACOG Committee on Practice Bulletins-Obstetrics committee member Mark Turrentine, MD. ABSTRACT: Group B streptococcus (GBS) is the leading cause of newborn infection. The primary risk factor for neonatal GBS early-onset disease (EOD) is maternal colonization

2020 American College of Obstetricians and Gynecologists

191. Expression of hepatitis B virus-specific markers in asymptomatic hepatitis B surface antigen carriers. Full Text available with Trip Pro

Expression of hepatitis B virus-specific markers in asymptomatic hepatitis B surface antigen carriers. A study was undertaken to assess the state of hepatitis B virus infection in a group of asymptomatic hepatitis B surface antigen (HBsAg) carriers. This study confirmed that the presence of hepatitis B e antigen (HBeAg) in serum was closely associated with serum HBsAg-specific deoxyribonucleic acid polymerase activity, hepatitis B core antigen (HBcAg) in serum and liver cell nuclei (...) , and a histological picture of chronic hepatitis. No HBsAg-specific deoxyribonucleic acid polymerase activity or HBcAg was detected in highly concentrated anti-HBe-positive sera. In addition, liver biopsy specimens from carriers with anti-HBe were negative for HbcAg by immunofluorescence, and the liver histology was either normal or revealed only fatty changes. These data indicate that the anti-HBe-positive sera contained either no Dane particles or, if present, at least a 500-fold-lower concentration of Dane

1977 Infection and immunity

192. Classification and sensitivity analysis of the transmission dynamic of hepatitis B Full Text available with Trip Pro

Classification and sensitivity analysis of the transmission dynamic of hepatitis B Hepatitis B infection caused by the hepatitis B virus is one of the most serious viral infections and a global health problem. In the transmission of hepatitis B infection, three different phases, i.e. acute infected, chronically infected, and carrier individuals, play important roles. Carrier individuals are especially significant, because they do not exhibit any symptoms and are able to transmit the infection (...) . Here we assessed the transmissibility associated with different infection stages of hepatitis B and generated an epidemic model.To demonstrate the transmission dynamic of hepatitis B, we investigate an epidemic model by dividing the infectious class into three subclasses, namely acute infected, chronically infected, and carrier individuals with both horizontal and vertical transmission.Numerical results and sensitivity analysis of some important parameters are presented to show that the proportion

2017 Theoretical biology & medical modelling

193. A critical role of hepatitis B virus polymerase in cirrhosis, hepatocellular carcinoma, and steatosis Full Text available with Trip Pro

A critical role of hepatitis B virus polymerase in cirrhosis, hepatocellular carcinoma, and steatosis Hepatitis B is one of the most common infectious diseases in the world; more than 350 million people are carriers of hepatitis B virus (HBV). Chronic HBV infection (CHB) leads to liver diseases such as cirrhosis, hepatocellular carcinoma (HCC), and steatosis. Despite its seriousness in terms of public health, the pathogenic mechanism of how CHB leads to liver diseases, especially cirrhosis

2017 FEBS open bio

194. Immunopathogenesis of Hepatitis B Virus. Full Text available with Trip Pro

Immunopathogenesis of Hepatitis B Virus. Chronic hepatitis B virus (HBV) infection is a global public health issue. There are >250 million people chronically infected with HBV, and these chronic carriers are at high risk of developing end-stage liver diseases and hepatocellular carcinoma. Patients with chronic hepatitis B (CHB) usually acquire the virus perinatally, while most patients infected during adulthood develop acute hepatitis B (AHB), which usually results in viral clearance. HBV

2017 Journal of Infectious Diseases

195. Genome-wide association study identifies a new locus at 7q21.13 associated with hepatitis B virus-related hepatocellular carcinoma. Full Text available with Trip Pro

Genome-wide association study identifies a new locus at 7q21.13 associated with hepatitis B virus-related hepatocellular carcinoma. Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. In China, chronic hepatitis B virus (HBV) infection remains the major risk factor for HCC. In this study, we performed a genome-wide association study (GWAS) among Chinese populations to identify novel genetic loci contributing to susceptibility to HBV-related HCC.Experimental (...) Design: GWAS scan is performed in a collection of 205 HBV-related HCC trios (each trio includes an affected proband and his/her both parents), and 355 chronic HBV carriers with HCC (cases) and 360 chronic HBV carriers without HCC (controls), followed by two rounds of replication studies totally consisting of 3,796 cases and 2,544 controls.Results: We identified a novel association signal within the CDK14 gene at 7q21.13 (index rs10272859, OR = 1.28, P = 9.46 × 10-10). Furthermore, we observed

2017 Clinical Cancer Research

196. Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk. Full Text available with Trip Pro

Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk. Hepatitis B surface antigen (HBsAg) and viral load are both hallmarks of hepatitis B virus (HBV) infection and have potential to stratify liver cancer risk.We carried out a nested case-control study including 211 liver cancer cases and 221 controls who were seropositive for HBsAg within two population-based cohorts in Shanghai. Logistic regression was performed to estimate the odds ratios (...) . Chronic HBsAg carriers may be suggested to simultaneously lower the viral load to < 2000 IU/ml and HBsAg level to < 100 IU/ml to lower their liver cancer risk.© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

2017 Journal of gastroenterology and hepatology

197. Pediatric hepatitis B treatment Full Text available with Trip Pro

Pediatric hepatitis B treatment Although the introduction of hepatitis B vaccine has been contributing to the reduction in the prevalence of hepatitis B virus (HBV) carriers worldwide, the treatment of children with chronic HBV infection is a challenge to be addressed. HBeAg seroconversion, which induces low replication of HBV, is widely accepted as the first goal of antiviral treatment in children with chronic hepatitis B. However, spontaneous HBeAg seroconversion is highly expected (...) in children with chronic HBV infection. Therefore, the identification of children who need antiviral treatment to induce HBeAg seroconversion is essential in the management of chronic HBV infection. Guidelines and experts' opinion show how to identify children who should be treated and how to treat them. If decompensated cirrhosis is absent, interferon-alpha is the first-line antiviral treatment. Nucleos(t)ide analogues (NAs), such as lamivudine, adefovir, entecavir and tenofovir, are also available

2017 Annals of Translational Medicine

198. Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features Full Text available with Trip Pro

Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features The data on hepatitis b virus (HBV) infection in immigrants population are scanty. The porpoise of this study was to define the demographic, virological, and clinical characteristics of subjects infected with HBV chronic infection in a cohort of immigrants living in Naples, Italy.A screening for HBV infection was offered to 1,331 immigrants, of whom 1,212 (91 (...) their diagnostic itinerary at a third-level infectious disease unit: 29 (32.2%) were asymptomatic non-viremic HBsAg carriers, 43 (47.8%) were asymptomatic viremic carriers, 14 (15.6%) had chronic hepatitis, and four (4.4%) had liver cirrhosis, with superimposed hepatocellular carcinoma in two.The data illustrate the demographic, clinical and virological characteristics of HBV infection in immigrants in Italy and indicate the need for Italian healthcare authorities to enhance their support for providing

2017 Infectious diseases of poverty

199. Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies Full Text available with Trip Pro

Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies Most people develop acute hepatitis B virus (HBV)-related hepatitis that is controlled by both humoral and cellular immune responses following acute infection. However, a number of individuals in HBV-endemic areas fail to resolve the infection and consequently become chronic carriers. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue (...) . Standard treatment in HBV infection includes IFN-α, nucleoside, or nucleotide analogs, which has direct antiviral activity and immune modulatory capacities. However, immunological control of the virus is often not durable. A robust T-cell response is associated with control of HBV infection and liver damage; however, HBV-specific T cells are deleted, dysfunctional, or become exhausted in chronic hepatitis patients. As a result, efforts to restore virus-specific T-cell immunity in chronic HBV patients

2017 Frontiers in immunology

200. Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus Full Text available with Trip Pro

Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus Hepatitis B virus (HBV) is a blood-borne pathogen responsible for chronic hepatitis, cirrhosis, and liver cancer. The mechanism of HBV entry into hepatocytes remains to be investigated. Recently, sodium taurocholate cotransporting polypeptide (NTCP) was discovered as a major HBV receptor based on an in vitro infection system using NTCP-reconstituted HepG2 cells. However, this infection (...) . This system based on the HepG2-NTCP-AS cells can support in vitro infection with HBV genotypes B and C, as well as using serum samples from HBeAg positive and negative chronic carriers. In summary, our study provides a PEG-free infection system closely resembling human natural infection. In addition, it points to a future research direction for heparin and heparin-binding host factor(s) in the blood, which are potentially involved in viral entry. To our knowledge, this is the first soluble and circulatory

2017 Scientific reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>